JP2007518764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007518764A5 JP2007518764A5 JP2006550032A JP2006550032A JP2007518764A5 JP 2007518764 A5 JP2007518764 A5 JP 2007518764A5 JP 2006550032 A JP2006550032 A JP 2006550032A JP 2006550032 A JP2006550032 A JP 2006550032A JP 2007518764 A5 JP2007518764 A5 JP 2007518764A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- drug
- fatty acid
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001495 Disorganized Schizophrenia Diseases 0.000 claims 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 claims 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000036983 biotransformation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 150000005691 triesters Chemical class 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2004A000069 | 2004-01-21 | ||
| IT000069A ITMI20040069A1 (it) | 2004-01-21 | 2004-01-21 | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| PCT/EP2005/000522 WO2005070411A1 (en) | 2004-01-21 | 2005-01-20 | USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007518764A JP2007518764A (ja) | 2007-07-12 |
| JP2007518764A5 true JP2007518764A5 (enExample) | 2008-03-06 |
| JP5087280B2 JP5087280B2 (ja) | 2012-12-05 |
Family
ID=34803698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550032A Expired - Fee Related JP5087280B2 (ja) | 2004-01-21 | 2005-01-20 | 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8829048B2 (enExample) |
| EP (1) | EP1706106B9 (enExample) |
| JP (1) | JP5087280B2 (enExample) |
| DE (1) | DE602005015415D1 (enExample) |
| DK (1) | DK1706106T3 (enExample) |
| ES (1) | ES2329809T3 (enExample) |
| HR (1) | HRP20090550T1 (enExample) |
| IT (1) | ITMI20040069A1 (enExample) |
| PL (1) | PL1706106T3 (enExample) |
| PT (1) | PT1706106E (enExample) |
| RS (1) | RS51195B (enExample) |
| WO (1) | WO2005070411A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| EP1772146A1 (en) * | 2005-10-03 | 2007-04-11 | Neuropharma, S.A. | Polyunsaturated fatty acids as bace inhibitors |
| EP2364701A1 (en) | 2005-12-20 | 2011-09-14 | Cenestra, Llc | Omega-3 fatty acid formulations |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| AU2008231570C1 (en) | 2007-03-28 | 2014-11-27 | Aker Biomarine Human Ingredients As | Bioeffective krill oil compositions |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| AU2008361645A1 (en) * | 2008-09-09 | 2010-03-18 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| CN107580457A (zh) | 2015-02-11 | 2018-01-12 | 阿克海洋生物南极股份公司 | 脂质组合物 |
| ES2937960T5 (en) | 2015-02-11 | 2026-02-16 | Aker Biomarine Human Ingredients As | Lipid extraction processes |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| EP3586642A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Ala enriched polyunsaturated fatty acid compositions |
| EP3586643A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| PL238670B1 (pl) * | 2018-07-06 | 2021-09-20 | Skotan Spolka Akcyjna | Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych |
| JPWO2022050355A1 (enExample) * | 2020-09-04 | 2022-03-10 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| IT1205043B (it) * | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
| DE3739700A1 (de) * | 1987-11-24 | 1989-06-08 | Guenther Dr Med Jeschke | Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin |
| JP2524217B2 (ja) | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| GB2218904A (en) | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
| GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| FR2688145B1 (fr) | 1992-03-06 | 1994-09-23 | Borden France Sa | Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur. |
| JPH0672868A (ja) * | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
| GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| ES2195175T3 (es) * | 1996-10-11 | 2003-12-01 | Scarista Ltd | Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico. |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| DE60022987T2 (de) | 2000-05-22 | 2006-10-19 | Pro Aparts - Investimentos E Consultoria Lda., Funchal | Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält |
| IT1320180B1 (it) * | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
| US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
-
2004
- 2004-01-21 IT IT000069A patent/ITMI20040069A1/it unknown
-
2005
- 2005-01-20 RS RSP-2009/0437A patent/RS51195B/sr unknown
- 2005-01-20 WO PCT/EP2005/000522 patent/WO2005070411A1/en not_active Ceased
- 2005-01-20 PT PT05701068T patent/PT1706106E/pt unknown
- 2005-01-20 EP EP05701068A patent/EP1706106B9/en not_active Revoked
- 2005-01-20 PL PL05701068T patent/PL1706106T3/pl unknown
- 2005-01-20 ES ES05701068T patent/ES2329809T3/es not_active Expired - Lifetime
- 2005-01-20 US US10/586,863 patent/US8829048B2/en not_active Expired - Fee Related
- 2005-01-20 DE DE602005015415T patent/DE602005015415D1/de not_active Expired - Lifetime
- 2005-01-20 DK DK05701068T patent/DK1706106T3/da active
- 2005-01-20 JP JP2006550032A patent/JP5087280B2/ja not_active Expired - Fee Related
- 2005-01-20 HR HR20090550T patent/HRP20090550T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007518764A5 (enExample) | ||
| RU2260423C2 (ru) | Этил-эпк с высокой степенью чистоты и другие производные эпк для психиатрических и неврологических расстройств | |
| ES2613606T3 (es) | Uso de derivados de ácidos grasos polinsaturados como medicamentos | |
| JP4415243B2 (ja) | 脂肪酸の治療効果の増強作用 | |
| TWI285549B (en) | Therapeutic combinations of fatty acids | |
| HRP20090550T1 (hr) | UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA | |
| JP2014512351A5 (enExample) | ||
| AU2002255164A1 (en) | Potentiation of therapeutic effects of fatty acids | |
| RU2001121185A (ru) | Этил-ЭПК с высокой степенью чистоты и другие производные ЭПК для психиатрических и неврологических расстройств | |
| JP2008540394A5 (enExample) | ||
| JP2015527386A5 (enExample) | ||
| JP7118642B2 (ja) | 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物 | |
| RU2019110681A (ru) | Фармацевтическая композиция | |
| JP2016501248A5 (enExample) | ||
| JP2020182497A5 (enExample) | ||
| WO2020255123A1 (en) | Composition comprising polar lipids and method of making same | |
| JP2017511387A5 (enExample) | ||
| WO2005046668A1 (ja) | 言語障害予防・治療剤 | |
| JP2008531675A5 (enExample) | ||
| Asuku et al. | The Role of Omega-3 Fatty Acids in Mental Health | |
| JP2017522278A5 (enExample) | ||
| HK1064310A (en) | Highly purified epa and derivatives for psychiatric and neurological disorders |